Active — Not RecruitingNot Applicable

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

Spain717 participantsStarted 2022-03-14

Plain-language summary

This registry will provide exploratory and descriptive information regarding contemporary practice patterns of parenteral antiplatelet therapy in the PCI (Percutaneous Coronary Intervention) setting and will investigate as well the short-term effectiveness and safety of the currently available parenteral antiplatelet agents in a cohort of "real-world" patients undergoing PCI in Spain.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Undergoing a PCI * Use of a parenteral antiplatelet agent (GPIs or cangrelor)during the invasive procedure (PCI) Exclusion Criteria: * Blood dyscrasia, bleeding diathesis or active bleeding at the time of the index procedure. * Chronic oral anticoagulation. * Recent history of stroke, TIA (Transient Ischemic Attack)or intracranial bleeding (\<3 months prior to inclusion). * Severe anemia (Hb\<9g/dl) or platelet count \<100x106/ml at the time of the index procedure. * Any active neoplasm.

What they're measuring

Rate of Net Adverse Clinical Events (NACE)

Timeframe: 48 hours

Trial details

NCT IDNCT05193019

SponsorFundación EPIC

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-01

View on ClinicalTrials.gov More Ischemic Heart Disease trials